ABEO
Price:
$6.25
Market Cap:
$270.71M
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biophar...[Read more]
Industry
Biotechnology
IPO Date
1980-09-19
Stock Exchange
NASDAQ
Ticker
ABEO
According to Abeona Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.53. This represents a change of 10.65% compared to the average of -0.03 of the last 4 quarters.
The mean historical PE Ratio of Abeona Therapeutics Inc. over the last ten years is -5.13. The current -3.53 PE Ratio has changed 6.79% with respect to the historical average. Over the past ten years (40 quarters), ABEO's PE Ratio was at its highest in in the June 2024 quarter at 5.67. The PE Ratio was at its lowest in in the September 2017 quarter at -32.21.
Average
-5.13
Median
-2.06
Minimum
-24.16
Maximum
-0.25
Discovering the peaks and valleys of Abeona Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.45%
Maximum Annual PE Ratio = -0.25
Minimum Annual Increase = -117.65%
Minimum Annual PE Ratio = -24.16
Year | PE Ratio | Change |
---|---|---|
2023 | -1.98 | 159.68% |
2022 | -0.76 | 101.52% |
2021 | -0.38 | -77.06% |
2020 | -1.65 | -23.31% |
2019 | -2.15 | -64.14% |
2018 | -5.99 | -75.21% |
2017 | -24.16 | 218.74% |
2016 | -7.58 | 18.73% |
2015 | -6.38 | 2.45% |
2014 | -0.25 | -117.65% |
The current PE Ratio of Abeona Therapeutics Inc. (ABEO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.04
5-year avg
-1.38
10-year avg
-5.13
Abeona Therapeutics Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-1.02), less than Athira Pharma, Inc. (-0.20), less than Fortress Biotech, Inc. (-0.77), less than ACADIA Pharmaceuticals Inc. (80.22), less than Cabaletta Bio, Inc. (-2.04), less than Calithera Biosciences, Inc. (0), less than Affimed N.V. (-0.00), less than Checkpoint Therapeutics, Inc. (-0.58), less than Adaptimmune Therapeutics plc (-3.02), less than Mereo BioPharma Group plc (-2.80), greater than Pieris Pharmaceuticals, Inc. (-18.01), less than PDS Biotechnology Corporation (-0.94), less than Leap Therapeutics, Inc. (-2.89), less than X4 Pharmaceuticals, Inc. (-2.43), less than Terns Pharmaceuticals, Inc. (5.90), greater than Day One Biopharmaceuticals, Inc. (-5.39), greater than Inozyme Pharma, Inc. (-16.94), less than REGENXBIO Inc. (-3.05), less than Anebulo Pharmaceuticals, Inc. (-1.84), greater than Invivyd, Inc. (-5.79), less than Black Diamond Therapeutics, Inc. (-0.53), less than null (-1.98),
Company | PE Ratio | Market cap |
---|---|---|
-1.02 | $32.69M | |
-0.20 | $23.29M | |
-0.77 | $52.37M | |
80.22 | $2.46B | |
-2.04 | $181.23M | |
0 | $34.11K | |
-0.00 | $49.64M | |
-0.58 | $155.56M | |
-3.02 | $196.39M | |
-2.80 | $658.11M | |
-18.01 | $22.84M | |
-0.94 | $117.82M | |
-2.89 | $143.11M | |
-2.43 | $87.45M | |
5.90 | $585.99M | |
-5.39 | $1.29B | |
-16.94 | $273.52M | |
-3.05 | $434.43M | |
-1.84 | $47.72M | |
-5.79 | $109.12M | |
-0.53 | $163.30M | |
-1.98 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Abeona Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Abeona Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Abeona Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Abeona Therapeutics Inc. (ABEO)?
What is the highest PE Ratio for Abeona Therapeutics Inc. (ABEO)?
What is the 3-year average PE Ratio for Abeona Therapeutics Inc. (ABEO)?
What is the 5-year average PE Ratio for Abeona Therapeutics Inc. (ABEO)?
How does the current PE Ratio for Abeona Therapeutics Inc. (ABEO) compare to its historical average?